Clinical Trials
17 trialsNCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
NCT03671590 2024-07-19
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
TG Therapeutics, Inc.
Phase 1 Terminated
NCT02742090 2024-07-03
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03828448 2023-07-24
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
TG Therapeutics, Inc.
Phase 2 Terminated
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03364231 2023-06-23
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
Phase 2 Completed
NCT02656303 2023-06-22
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
TG Therapeutics, Inc.
Phase 2 Terminated
NCT02535286 2022-10-20
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
TG Therapeutics, Inc.
Phase 1 Completed
NCT03379051 2022-08-22
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
Phase 1/2 Terminated
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03207256 2022-07-21
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
TG Therapeutics, Inc.
Phase 2 Terminated
NCT01767766 2021-08-23
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02006485 2019-11-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02100852 2019-10-02
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
TG Therapeutics, Inc.
Phase 1 Completed
NCT02164006 2019-10-02
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
TG Therapeutics, Inc.
Phase 1 Completed
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed